1996
DOI: 10.1126/science.274.5291.1363
|View full text |Cite
|
Sign up to set email alerts
|

Melanoma Cell Expression of Fas(Apo-1/CD95) Ligand: Implications for Tumor Immune Escape

Abstract: Malignant melanoma accounts for most of the increasing mortality from skin cancer. Melanoma cells were found to express Fas (also called Apo-1 or CD95) ligand (FasL). In metastatic lesions, Fas-expressing T cell infiltrates were proximal to FasL+ tumor cells. In vitro, apoptosis of Fas-sensitive target cells occurred upon incubation with melanoma tumor cells; and in vivo, injection of FasL+ mouse melanoma cells in mice led to rapid tumor formation. In contrast, tumorigenesis was delayed in Fas-deficient lpr mu… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
2

Citation Types

24
753
7
13

Year Published

1998
1998
2009
2009

Publication Types

Select...
9

Relationship

0
9

Authors

Journals

citations
Cited by 1,171 publications
(797 citation statements)
references
References 30 publications
24
753
7
13
Order By: Relevance
“…Our flow cytometry data on magnetically separated T cells was supported by our data from four-colour flow cytometry; there was a reasonable concordance between the two methods in estimating the percentage of apoptotic T cells. Apoptosis of tumour-infiltrating lymphocytes has also been demonstrated in other tumours, including melanoma, colon cancer and hepatocellular carcinoma (Hahne et al, 1996, O'Connell et al, 1996and Strand et al, 1996.…”
Section: Discussionmentioning
confidence: 94%
“…Our flow cytometry data on magnetically separated T cells was supported by our data from four-colour flow cytometry; there was a reasonable concordance between the two methods in estimating the percentage of apoptotic T cells. Apoptosis of tumour-infiltrating lymphocytes has also been demonstrated in other tumours, including melanoma, colon cancer and hepatocellular carcinoma (Hahne et al, 1996, O'Connell et al, 1996and Strand et al, 1996.…”
Section: Discussionmentioning
confidence: 94%
“…There are significant advantages in using combined therapy for cancer treatment. Since FasL expression and activity could be "naturally" restored in highly metastatic tumors through epigenetic and genetic changes [1,4,5], we have attempted to evoke FasL-mediated apoptotic death in Faspositive melanomas. Our first attempt was to modulate the FasL transcription [45,46,59,61,[86][87][88].…”
Section: Discussionmentioning
confidence: 99%
“…On the other hand, cancer development is often accompanied by the suppression of the surface Fas receptor expression and/or inactivation of the Fas-mediated signaling, potentially resulting in an inhibition of immuno-logical anticancer surveillance in vivo [3]. In some highly metastatic cancer cells, including Fas-negative melanomas, Fas Ligand (FasL) surface expression is restored, providing an additional mechanism to suppress anticancer immune effector cells (so called "tumor counterattack") [4,5]. Alternatively, secretion of processed "soluble" FasL [6] or FasL-bearing microvesicles [7] by cancer cells may create a specific shield, which allows them to dampen the effects of cytotoxic lymphocytes or natural killer cells.…”
Section: Introductionmentioning
confidence: 99%
“…45,46 The use of mFasL as a treatment for GBM has been studied in the rat F98 glioma model, in which survival time was extended by 50% in rats treated with RAdhCMV-mFasL compared with the control animals. 19 Clinical trials assessing the feasibility and adverse side effect of RAds delivering HSV1 -TK for the treatment of GBM have started.…”
Section: Discussionmentioning
confidence: 99%